CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $152,634,215 | +59.9% | 5,132,287 | -3.1% | 1.98% | +64.6% |
| Q2 2023 | $95,471,546 | +12.4% | 5,298,088 | +0.2% | 1.20% | +1.1% |
| Q1 2023 | $84,949,675 | -17.5% | 5,289,519 | -6.0% | 1.19% | -22.3% |
| Q4 2022 | $102,932,815 | -6.9% | 5,624,744 | -0.1% | 1.54% | -8.4% |
| Q3 2022 | $110,612,000 | +8.3% | 5,631,958 | +2.9% | 1.68% | +1.3% |
| Q2 2022 | $102,099,000 | -5.9% | 5,474,459 | +10.7% | 1.65% | +24.1% |
| Q1 2022 | $108,521,000 | -20.3% | 4,944,013 | +3.1% | 1.33% | -4.1% |
| Q4 2021 | $136,187,000 | +115.8% | 4,793,638 | +59.9% | 1.39% | +85.8% |
| Q3 2021 | $63,119,000 | +23.7% | 2,998,512 | +10.7% | 0.75% | +10.7% |
| Q2 2021 | $51,043,000 | +66.7% | 2,707,825 | +35.1% | 0.68% | +49.6% |
| Q1 2021 | $30,616,000 | +49.2% | 2,003,688 | +37.8% | 0.45% | +36.6% |
| Q4 2020 | $20,515,000 | +49.6% | 1,453,966 | +66.2% | 0.33% | +17.8% |
| Q3 2020 | $13,709,000 | -11.8% | 874,842 | -1.3% | 0.28% | -25.7% |
| Q2 2020 | $15,536,000 | – | 886,762 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |